{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "8737631", "DateCompleted": {"Year": "1996", "Month": "11", "Day": "08"}, "DateRevised": {"Year": "2012", "Month": "11", "Day": "15"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0004-4172", "JournalIssue": {"Volume": "46", "Issue": "5", "PubDate": {"Year": "1996", "Month": "May"}}, "Title": "Arzneimittel-Forschung", "ISOAbbreviation": "Arzneimittelforschung"}, "ArticleTitle": "Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency.", "Pagination": {"StartPage": "483", "EndPage": "487", "MedlinePgn": "483-7"}, "Abstract": {"AbstractText": ["Oxerutins (O-(beta-hydroxyethyl)rutosides, HR, Venoruton) and horse chestnut extract (HCE) are active principles of first priority for the pharmacological treatment of chronic venous insufficiency (CVI). The efficacies of both compounds were shown in numerous, double-blind, randomized, placebo controlled clinical trials. Besides the direct comparison of the two compounds the aim of the study was to investigate the initial dose/maintenance dose concept for HR. 137 female, postmenopausal patients with CVI II finished the study according to protocol. Following one week placebo run-in the patients were treated either with 1000 mg/d HR, 600 mg/d HCE or 1000 mg/d for 4 weeks and than with 500 mg/d HR within the initial dose/maintainance dose concept for 12 weeks and observed for further 6 weeks. A main confirmative criterion was the volume reduction of the leg. Subjective criteria were descriptively evaluated. HR (1000 mg/d) was proven to be equivalent or better, reducing the leg volume (AUB0-18) by -5273 +/- 11418 ml.d compared to -3187 +/- 10842 ml.d under HR (1000 mg/d and 500 mg/d), and -3004 +/- 7429 ml.d under HCE-treatment. Both compounds exhibit a substantial carry-over effect. The maintenance posology of HR is able to stabilize the therapeutic obtained under initial dose conditions."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zyma GmbH, Medizin und Entwicklung, Munich, Germany."}], "LastName": "Rehn", "ForeName": "D", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Unkauf", "ForeName": "M", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Klein", "ForeName": "P", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Jost", "ForeName": "V", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "L\u00fccker", "ForeName": "P W", "Initials": "PW"}], "PublicationTypeList": ["Clinical Trial", "Comparative Study", "Journal Article", "Multicenter Study", "Randomized Controlled Trial"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Arzneimittelforschung", "NlmUniqueID": "0372660", "ISSNLinking": "0004-4172"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Hydroxyethylrutoside"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Vasoconstrictor Agents"}, {"RegistryNumber": "7Y4N11PXO8", "NameOfSubstance": "troxerutin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": [], "DescriptorName": "Bandages"}, {"QualifierName": [], "DescriptorName": "Chronic Disease"}, {"QualifierName": [], "DescriptorName": "Combined Modality Therapy"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["adverse effects", "analogs & derivatives", "therapeutic use"], "DescriptorName": "Hydroxyethylrutoside"}, {"QualifierName": ["anatomy & histology"], "DescriptorName": "Leg"}, {"QualifierName": [], "DescriptorName": "Microcirculation"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Vasoconstrictor Agents"}, {"QualifierName": ["drug therapy", "pathology", "therapy"], "DescriptorName": "Venous Insufficiency"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1996", "Month": "5", "Day": "1"}, {"Year": "1996", "Month": "5", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1996", "Month": "5", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["8737631"]}}]}